[BostonCard]

On monoclonal abs....

https://www.nytimes.com/2020/10/02/healt...tment.html

Hard to say if he's only mildly symptomatic, though that may be peak effectiveness for the drug. If the president has a bad reaction from an unapproved drug.....eep! They should be generally safe, but...

Yup, would be a tough call.  And even remdisivir carries some risk; evaluating its safety is hard given that the studies were in hospitalized patients with a lot of other stuff going on.  Given the extraordinary circumstances, I might ask the companies to convene an emergency iDMC for ongoing studies and present the most up-to-date data in order to make the best risk/benefit assessment.  Timing is the issue; even under the best of circumstances it takes time to clean, prepare, and analyze the data.

BC

[BostonCard]

On monoclonal abs....

https://www.nytimes.com/2020/10/02/healt...tment.html

Hard to say if he's only mildly symptomatic, though that may be peak effectiveness for the drug. If the president has a bad reaction from an unapproved drug.....eep! They should be generally safe, but...

Yup, would be a tough call.  And even remdisivir carries some risk; evaluating its safety is hard given that the studies were in hospitalized patients with a lot of other stuff going on.  Given the extraordinary circumstances, I might ask the companies to convene an emergency iDMC for ongoing studies and present the most up-to-date data in order to make the best risk/benefit assessment.  Timing is the issue; even under the best of circumstances it takes time to clean, prepare, and analyze the data.

BC